BRAIN Biotech AG

As of June 30, 2026, BRAIN Biotech AG carries a market capitalization of 62.27M, placing it among publicly traded companies globally. Its enterprise value stands at 62.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BRAIN Biotech AG's next confirmed earnings release is scheduled for January 14, 2027.

As of June 30, 2026, BRAIN Biotech AG has 21.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.35, and the price-to-book ratio stands at -8.74.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 62.27M versus a market cap of 62.27M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BRAIN Biotech AG maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.20, reflecting losses generated across the asset base. The company generates approximately 163,555.16 in revenue per employee across its workforce of 281.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BRAIN Biotech AG recorded an income tax benefit of -461,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -14.43M and -13.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BRAIN Biotech AG's stock has gained approximately 23.18% over the past 52 weeks. The 50-day moving average sits at 2.73, while the 200-day moving average is 2.63.

Over the twelve months ended June 30, 2026, BRAIN Biotech AG generated 45.96M in revenue and converted that into -13.97M in net income, yielding earnings per share of -0.64. EBITDA reached -2.45M, while operating income came in at -8.14M.

These figures are as of June 30, 2026. Total book value stands at -7.12M, with working capital of 5.10M providing operational flexibility.

BRAIN Biotech AG produced -6.00M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BRAIN Biotech AG posted a gross margin of 58.84, reflecting its pricing power and cost economics. The operating margin of -17.71 and net profit margin of -30.41 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.90, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BRAIN Biotech AG shareholders.